Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Moodys
UBS
AstraZeneca
Colorcon
Julphar
US Army
Chinese Patent Office
McKinsey

Generated: December 10, 2018

DrugPatentWatch Database Preview

SUPRENZA Drug Profile

« Back to Dashboard

When do Suprenza patents expire, and what generic alternatives are available?

Suprenza is a drug marketed by Citius Pharms and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has fourteen patent family members in ten countries.

The generic ingredient in SUPRENZA is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.

Drug patent expirations by year for SUPRENZA
Synonyms for SUPRENZA
.alpha.-Methylamphetamine hydrochloride
.alpha.,.alpha.-Dimethylphenethylamine hydrochloride
(1,1-DIMETHYL-2-PHENYL)ETHYLAMINE HYDROCHLORIDE
0K2I505OTV
1-Phenyl-2-methyl-2-aminopropane hydrochloride
1-phenyl-2-methyl-2-aminopropanehydrochloride
1-Phenyl-2-methyl-2-propylamine Hydrochloride
1,1-Dimethyl-2-phenylethylamine hydrochloride
1197-21-3
122-09-8 (Parent)
2-Amino-2-methyl-1-phenylpropane hydrochloride
2-methyl-1-phenyl-2-propanamine hydrochloride
2-Methyl-1-phenylpropan-2-amine hydrochloride
2-methyl-1-phenylpropan-2-amine;hydrochloride
AC1L2F9M
Adipex-p (TN)
AK-81487
AKOS015891196
alpha-Methylamphetamine hydrochloride
alpha-methylamphetaminehydrochloride
alpha,alpha-dimethyl-phenethylaminhydrochloride
alpha,alpha-Dimethylphenethylamine hydrochloride
ANW-58508
AOB5784
API0007710
AS01627
BENZENEETHANAMINE, A,A-DIMETHYL-, HYDROCHLORIDE (1:1)
Benzeneethanamine, alpha,alpha-dimethyl-, hydrochloride
Benzeneethanamine, alpha,alpha-dimethyl, hydrochloride
Benzeneethanamine,.alpha.-dimethyl, hydrochloride
benzeneethanamine,alpha,alpha-dimethyl,hydrochloride
CCG-221139
CHEBI:50506
CHEMBL1200912
CTK6A7128
D05459
DEA No. 1640
DTXSID20152550
Duromine Hydrochloride
EINECS 214-821-9
Fastin
Fastin (TN)
FT-0673716
I01-8880
I14-44888
Inoamin Hydrochloride
Ionamin Hydrochloride
Linyl Hydrochloride
Lipopill Hydrochloride
Lomaira
Lonamin Hydrochloride
LS-103359
MG 18370
MG 18570
Mirapront Hydrochloride
MLS003882563
NCAIGTHBQTXTLR-UHFFFAOYSA-N
Normephentermine Hydrochloride
NSC 44090
NSC-44090
NSC44090
Obestin-30
Oby-Trim
Omnibex Hydrochloride
Ona-Mast
Ona-Mast hydrochloride
Phenethylamine, alpha,alpha-dimethyl-, hydrochloride
Phenteral
Phenteramine hydrochloride
Phentermine HCl
Phentermine hydrochloride
Phentermine hydrochloride (USP)
Phentermine hydrochloride [USAN]
Phentermine hydrochloride [USP]
Phentermine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Phentermyl Wyncaps
Phenyl-t-butylamine hydrochloride
phenyl-t-butylaminehydrochloride
Phenyl-tert-butylamine Hydrochloride
S 58
SCHEMBL41585
SMR000058739
TC-147253
TL8000587
Tora
UNII-0K2I505OTV
Wilpo (VAN)
Wilpo Hydrochloride
wilpohydrochloride
WLN: ZX1&1&1R &GH

US Patents and Regulatory Information for SUPRENZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for SUPRENZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 ➤ Sign Up ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 ➤ Sign Up ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SUPRENZA
Drugname Dosage Strength RLD Date
➤ Subscribe Orally Disintegrating Tablets 37.5 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Orally Disintegrating Tablets 15 mg and 30 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
UBS
Moodys
Daiichi Sankyo
Accenture
Harvard Business School
Johnson and Johnson
Dow
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.